Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Hematologic Malignancies
Filter by Topic
Leukemia
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
By
Phoebe Starr
ASCO 2023 Highlights
,
Myelodysplastic Syndromes
,
Hematologic Malignancies
August 2023, Vol 14, No 4
Chicago, IL—Interim results from the phase 3 COMMANDS trial demonstrated that first-line treatment with luspatercept-aamt (Reblozyl) increased hemoglobin levels and enabled nearly twice as many patients with transfusion-dependent, lower-risk myelodysplastic syndromes (MDS) to avoid red blood cell transfusions during the first 24 weeks of the study compared with standard-of-care epoetin alfa.
Read Article
FDA Approves Columvi for Select Patients With Relapsed or Refractory Large B-Cell Lymphomas
FDA Approvals, News & Updates
,
Lymphoma
,
Hematologic Malignancies
August 2023, Vol 14, No 4
On
June 15, 2023
, the FDA accelerated the approval of glofitamab-gxbm (Columvi; Genentech), a bispecific CD20-directed CD3 T-cell engager, for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified, or large B-cell lymphoma arising from follicular lymphoma after ≥2 lines of systemic therapy.
Read Article
Epkinly FDA Approved for Treatment of Advanced Diffuse Large B-Cell Lymphoma
FDA Approvals, News & Updates
,
Lymphoma
,
Hematologic Malignancies
August 2023, Vol 14, No 4
On
May 19, 2023
, the FDA accelerated the approval of epcoritamab-bysp (Epkinly; Genmab US), a bispecific CD20-directed CD3 T-cell engager, for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma after ≥2 lines of systemic therapy.
Read Article
Vanflyta Now Approved for Newly Diagnosed FLT3-ITD–Positive AML
FDA Approvals, News & Updates
,
Leukemia
,
Hematologic Malignancies
August 2023, Vol 14, No 4
On
July 20, 2023
, the FDA approved quizartinib (Vanflyta; Daiichi Sankyo) with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy after consolidation chemotherapy, for the treatment of adults with newly diagnosed acute myeloid leukemia (AML) that is
FLT3
-internal tandem duplication (
ITD
)–positive, as detected by an FDA-approved test.
Read Article
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
By
Wayne Kuznar
NCCN
,
Leukemia
,
Lymphoma
,
NCCN 2023 Conference Highlights
,
Hematologic Malignancies
June 2023, Vol 14, No 3 - Online Only
In a session during the 2023 National Comprehensive Cancer Network (NCCN) Annual Conference, Deborah M. Stephens, DO, provided important updates to treatment recommendations for patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), and identified key factors for selecting frontline and subsequent therapies, including
IGHV
gene status, 17p deletion/
TP53
mutation status, age, patient comorbidities, and resistance mutations.
Read Article
Restrictive Diet May Not Be Necessary for Patients Undergoing HSCT
By
Phoebe Starr
ASH Highlights
,
Hematologic Malignancies
February 2023, Vol 14, No 1
Patients undergoing hematopoietic stem-cell transplantation (HSCT) do not derive any benefit from the restrictive diet frequently prescribed to prevent infections, according to the results of a clinical trial presented during the 64th American Society of Hematology Annual Meeting and Exposition.
Read Article
DETERMINATION Trial Confirms Importance of Individualizing Therapy for Newly Diagnosed Multiple Myeloma
By
Phoebe Starr
Hematologic Malignancies
October 2022, Vol 13, No 5
In the phase 3 DETERMINATION trial—in which patients with newly diagnosed multiple myeloma were randomly assigned to a standard triplet regimen with and without autologous stem-cell transplantation (ASCT), with all receiving lenalidomide (Revlimid) maintenance therapy until disease progression—patients with ASCT had significantly longer progression-free survival (PFS) versus those who did not, but no difference in overall survival (OS) was observed between the 2 treatment arms.
Read Article
CAR T-Cell Effective as Second-Line Treatment in Transplant-Ineligible Large B-Cell Lymphoma
By
Wayne Kuznar
Hematologic Malignancies
October 2022, Vol 13, No 5
More than 50% of adults with refractory or relapsed large B-cell lymphoma (LBCL) who were not deemed candidates for high-dose chemotherapy and hematopoietic stem-cell transplantation (HSCT) had complete responses (CRs) following treatment with the chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel (Breyanzi).
Read Article
Lisaftoclax Demonstrates Preliminary Efficacy and Tolerability in Relapsed or Refractory CLL/SLL
By
Phoebe Starr
Hematologic Malignancies
,
Leukemia
October 2021, Vol 12, No 5
The novel BCL-2 inhibitor, lisaftoclax (APG-2575), elicited encouraging responses and acceptable tolerability in patients with relapsed or refractory chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and other hematologic malignancies, according to results of a phase 1 study presented at the American Society of Clinical Oncology 2021 virtual annual meeting.
Read Article
Daratumumab in Newly Diagnosed Multiple Myeloma: Weighing the Pros and Cons
By
Chase Doyle
Hematologic Malignancies
October 2021, Vol 12, No 5
According to the American Cancer Society, nearly 35,000 new cases of multiple myeloma will be diagnosed in the United States in 2021, and approximately 12,410 deaths will be attributed to the disease.1 However, with the introduction of several novel therapies, the outcomes for patients with newly diagnosed multiple myeloma have improved significantly over the past decade.
Read Article
Page 1 of 11
1
2
3
4
5
6
7
8
9
10
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma